€2.5 billion net proceeds expected to be used for investments and acquisitions for specialty chemicals which should increase group profitability and reduce volatility
PeroxyChem will add $300 million of revenues, $60 million of EBITDA and enhances Evonik's market position, share of specialty chemicals and EBITDA margin with a negligible impact on leverage
A detailed rationale for the Baa1 stable rating of Evonik, assessing the ramifications of the acquisition of Air Products’ specialty & coating additives and Huber Silica businesses.